Table 1.
Imaging Method/Radionuclide | Sensitivity (%) | Specificity (%) | Function | Cost | Accessibility | Radiation | References | |
---|---|---|---|---|---|---|---|---|
Radiography | 43–86 | 27–83 | +++ | + | +++++ | ☢ | [50,51,52,53,54] | |
CT | 67–80 | 50–70 | +++ | +++ | +++ | ☢ | [50,55] | |
Ultrasound | 79 | 80 | ++ | + | +++++ | O | [56] | |
MRI | 87–100 | 37–83.8 | ++++ | +++ | +++ | O | [52,53,54,57,58,59,60,61,62] | |
Planar Bone Scintigraphy | 99mTc-MDP | 81.0–84.2 | 28.0–67.7 | +++ | ++ | ++ | ☢☢☢ | [52,54] |
Planar WBC Scan | 99mTc-besilesomab | 74.8 | 71.8 | +++ | +++ | ++ | ☢☢☢ | [63] |
99mTc-HMPAO | 59.0–91 | 79.5–92 | +++ | ++ | ++ | ☢☢☢ | [63,64] | |
99mTc-exametazime | 86.0 | 100 | +++ | ++ | ++ | ☢☢☢ | [65] | |
WBC SPECT/CT | 99mTc-WBC | 87.5–100 | 35–92 | ++++ | ++++ | + | ☢☢☢☢ | [58,62,66,67,68,69] |
99mTc-sulesomab | 67–72.0 | 85–88.0 | +++ | +++ | ++ | ☢☢☢☢ | [70,71] | |
111In-WBC | 74–92 | 68–75 | ++++ | ++++ | + | ☢☢☢☢ | [54,58] | |
PET | 18F-FDG | 81–92.3 | 92.0–93 | +++ | ++++ | + | ☢☢☢ | [72,73] |
PET/CT | 18F-FDG | 43–89 | 67–100 | ++++ | ++++ | + | ☢☢☢☢ | [58,65] |
67Ga-citrate | 44–100 | 45–77 | ++ | ++ | ++ | ☢☢☢ | [70,74] | |
68Ga-citrate | 100 | 76 | ++ | ++ | ++ | ☢☢☢ | [75] |
Note: Relative radiation level ratings for effective adult dose: O = 0 mSv, ☢ < 0.1 mSv, ☢☢☢ = 1–10 mSv, ☢☢☢☢ = 10–30 mSv. Utility of each technique was adapted from Noguerol et al. and is graded from most useful (+++++) to least useful (+) [76]. Radiation ratings are adapted from the 2019 ACR appropriateness criteria [49].